Gilead Sciences Inc.
Berger Dietmar Files Gilead Sciences (GILD) Form 4 - January 02, 2026
Transactions
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Berger Dietmar | 2026-01-02 | Sell | 6.9K | $121.60 | $844.4K | Direct |
| Berger Dietmar | 2026-01-02 | Buy | 16.3K | - | $0.00 | Direct |
| Berger Dietmar | 2026-01-02 | Sell | 16.3K | - | $0.00 | Direct |
Track GILD insider activity
Get alerts when Gilead Sciences Inc. executives trade their shares.
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Official SEC Documents